This site is intended for healthcare professionals only
LoginRegister

Metformin Reduces Risk of Diabetes by 22%, Results of Latest Meta-analysis - Video

  |  
  • whatsapp
  • Telegram

Overview

The addition of metformin to intensive Lifestyle Modifications (LSM) is an effective value addition among patients with pre-diabetes at high risk of progression to T2DM, a recent systematic review and meta-analysis study has concluded.

This study has been published in the June 2024 issue of Clinical Diabetology, Via Medica Journals.

The meta-analysis included 8,869 patients with prediabetes. Patients were grouped into two interventions- 4,328 in the metformin arm and 4,541 in the control arm (lifestyle modification/placebo).

Key highlights from the meta-analysis include:

  • The use of metformin resulted in a 22% relative risk reduction in the progression from prediabetes to diabetes compared to lifestyle modification and/or placebo.

This meta-analysis concludes that early intervention with metformin reduces the risk of type 2 diabetes in high-risk individuals with prediabetes1 . The huge global burden of prediabetes with an approximate 25% rate of conversion to diabetes represents the tip of the “sugary” iceberg.

These findings also co-relate with the most recently published analysis of UKPDS with regards to early intervention with metformin in T2D. Over the largest 42-year follow-up, the study showed that intensive glycemic control with metformin, compared to conventional glycemic control, led to a 20% reduction in the risk of death from any cause and a 31% reduction in the risk of myocardial infarction2.

*UKPDS: United Kingdom Prospective Diabetes Study

References:

1) Ghosal, S., Tippisetty, S., Polisetti, S., & Seshadri, K. G. (2024). Metformin for the Prevention of Prediabetes Progression to Type 2 Diabetes: A Systematic Review and Meta-Analysis. Clinical Diabetology, Via Medica Journals.

2) Adler, A. I., Coleman, R. L., Leal, J., Whiteley, W. N., Clarke, P. & Holman, R. R. (2024). Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91). Lancet, doi:10.1016/S0140-6736(24)00537-3

Speakers

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
X